Drug Profile
Pergolide
Alternative Names: Celance; LY 127809; PermaxLatest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antiparkinsonians; Ergolines; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 30 Aug 2007 Withdrawn for Parkinson's disease in Canada (PO)
- 29 Mar 2007 Withdrawn for Parkinson's disease in USA (PO)